We’re expanding our reach! 🚀 Therapeutic Advances in Gastroenterology is now on BlueSky—we’ll be sharing research, updates, and discussions there too. Follow us @TAGastroenterol on BlueSky so we can follow you back! 🔗 #Gastroenterology #BlueSky

RT @MANunezSanchez: Our special collection "Novel Insights into MASLD: From Mechanisms to Treatment" in @TAGastroenterol, is now open for s….

In a 240-patient cohort, fecal microbiota transplant for recurrent C. difficile infection failed in 24.6% of cases (18.3% recurrence, 7.1% death within 1 year). Older age, multiple prior episodes, and diabetes were significantly associated with failure.

In the phase IIIb CDI-SCOPE trial, fecal microbiota, live-jslm (REBYOTA®) delivered via colonoscopy prevented CDI recurrence in 95.1% of patients over 8 weeks. Only 9.8% experienced mild, RBL-related TEAEs. Safe, practical, and effective. 🔗

🩸 A 29-expert Delphi panel reached consensus on 36 statements for managing delayed post-polypectomy bleeding. Key recommendations: risk stratification to reduce unnecessary colonoscopies, and guidance for antithrombotic and hemostatic management. 🔗

🧠 In 1344 non-sedated EGD patients, a pre-procedural anxiety score >36 predicted higher odds of incomplete or poor-quality exams (AUC=0.720). Each 1-point increase in STAI-I raised failure odds by 3.8%. Routine anxiety screening could improve outcomes. 🔗

In unresectable perihilar cholangiocarcinoma, endoscopic therapy goes beyond biliary drainage. ERCP-based approaches + adjuncts like RFA, PDT & EUS methods offer therapeutic promise where surgery isn’t an option.

Smoking, MASLD, cerebrovascular disease, H. pylori persistence, multiple lesions & severe atrophic gastritis all linked to metachronous gastric cancer post-curative ESD. A nomogram showed strong predictive accuracy (C-index up to 0.845).

Anti-reflux mucosectomy significantly improved LES pressure, Hill’s grade, and GERD-related symptom scores vs argon plasma coagulation in Barrett’s esophagus. A stronger reflux barrier with lower lesion residue—supporting ARMS as a dual-target strategy.

In MASLD and MetALD, current smoking significantly worsened survival and increased risks of cirrhosis, CVD, and liver-related mortality. Never smokers had lowest risks across most outcomes. 📊 Supports strong cessation strategies in liver disease care.

Thanks to @berry_parul, Rohan Raju Dhanakshirur & @Khanna_S for this structured and clinically grounded roadmap for LLM use in gastroenterology.

🧠 LLMs show promise for GI research—supporting clinical decisions, data extraction & patient comms—but risks like hallucinations & bias remain. This framework outlines practical steps: goal-setting, fine-tuning, EHR integration & real-world validation. 🔗

Thanks to Robert Dorrell, Alexa Cecil, @swati_pawa, Gregory Russell & @rishipawa for this data-driven call for individualized LAMS removal timing in endoscopic necrosectomy.

🧠 In 104 patients with walled-off necrosis, tailoring LAMS dwell time by imaging & symptoms led to similar success & safety—despite longer stent time (>4wks) in necrosis-heavy cases. Early removal = fewer necrosectomies. Read more:

🚨 For massive rectal GISTs >5cm, transanal endoscopic resection (taLR) matched radical surgery on 5-yr DFS (94.1% vs 100%, p=0.405), while reducing OR time, hospital stay & preserving anal function. A QoL-preserving alternative. Read here:

RT @JonnyBlackwell: I think this is important but must only be done fully explaining to the patient that it is an unevidenced intervention….

🆘 In 6 patients with corticosteroid + infliximab-refractory acute severe UC, JAK inhibitors (upadacitinib/tofacitinib) led to clinical response in 4/6 within 72h. All responders were colectomy-free and in steroid-free remission by day 90. Read here:

Thanks to Pilar Nos and colleagues for this real-world snapshot of treatment patterns, symptom burden, and persistent quality of life issues in UC. A timely reminder that satisfaction doesn’t always mean success in IBD care. @pilarnos.

📊 Despite treatment satisfaction, 29% of Spanish adults with UC still had moderate-to-severe disease, frequent flares, and impaired QoL. Real-world data show clear unmet needs remain—especially for those on biologics or JAK inhibitors. Read here:

Thanks to @MatFume, @BuissonPr, and colleagues for these reassuring REMSWITCH data on SC infliximab in Crohn’s with perianal involvement. Important real-world evidence for daily practice.

Switching from IV to SC infliximab was safe in patients with perianal Crohn’s disease: no new lesions over 18 months; 2/3 with active lesions at baseline achieved resolution. Only 1 relapse (2.5%) recaptured remission with SC dose intensification. Read: